Biopharmaceutical company Aridis Pharmaceuticals Inc (Nasdaq:ARDS) on Tuesday announced an agreement with the US Food and Drug Administration (FDA) to simplify its AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis (CF) in collaboration with the CF Foundation.
The company said AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients.
Upon achieving positive Phase 1 safety data in healthy adults exposed to a single ascending dose (SAD) or a multiple ascending dose (MAD) regimen, the company has proposed to streamline AR-501's Phase 2a clinical trial in CF patients in only the MAD regimen.
Additionally, the FDA has accepted the company's proposal to expand the originally planned Phase 2a protocol design into a Phase 2a/2b study, which will enable seamless and efficient advancement from Phase 2a into Phase 2b using the same clinical study protocol. The data from the Phase 2a will inform the dose selection and sample size expansion to achieve statistical significance in efficacy in Phase 2b.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera